Latest blogs by Tami Cannizzaro
More blogs by Tami Cannizzaro
#1 Small Business Software
See why business owners choose Thryv over any other software.
#1 Small Business SoftwareLearn MoreOnboarding & Support
Experience our unmatched, onboarding and support team.
Onboarding & SupportLearn MoreCustomer Reviews
Don’t take our word for it, see what our users say about Thryv.
Customer ReviewsLearn MoreCompare Thryv
We work with the softwares that you love.
Compare ThryvLearn More#1 Small Business Software
See why business owners choose Thryv over any other software.
#1 Small Business SoftwareLearn MoreOnboarding & Support
Experience our unmatched, onboarding and support team.
Onboarding & SupportLearn MoreCustomer Reviews
Don’t take our word for it, see what our users say about Thryv.
Customer ReviewsLearn MoreCompare Thryv
We work with the softwares that you love.
Compare ThryvLearn MoreTami Cannizzaro
Chief Marketing Officer
Tami Cannizzaro is a widely respected industry veteran who has held senior executive roles at some of the most important category-defining companies in the world including IBM, eBay, Oracle, Forcepoint & Thryv. Proven ability to rapidly build high performance marketing teams and drive category market leadership. Outstanding track record building pipeline on a global basis for SaaS businesses. In depth expertise all facets of marketing, including product marketing, demand generation, digital marketing, social media, Web, SaaS, communications, investor relations, channel & partner marketing, marketing technology, analytics, tele-prospecting and sales enablement.
More blogs by Tami Cannizzaro
Create your free Thryv account today
See how Command Center can simplify your communications.
Use for freeCopyright @ 2025 Thryv, Inc.
Terms and conditions apply. Free plans have limited functionality. Upgraded plans with more functionality are available for a fee. See https://corporate.thryv.com/terms/ for plan and pricing details.
Goodbyes are so hard.
Why don’t you try Thryv to see if it’s meant to be? Enjoy a 2-week trial on us.